Dublin, Oct. 04, 2023 (GLOBE NEWSWIRE) -- The "Somatropin Market, By Dosage Form, By Application, By Distribution Channel, and By Region (North America, Latin America, Europe, Asia Pacific, Middle ...

The product, lonapegsomatropin, is a sustained-release formulation and could replace daily injections. The FDA recently approved the first once-weekly somatropin injection for pediatric patients 1 ...

March 5, 2010 — The US Food and Drug Administration (FDA) has approved a prefilled somatropin (rDNA origin) injection pen (Norditropin FlexPro, Novo Nordisk, Inc) for the treatment of growth hormone ...

COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved somatropin pre-filled injection pens for the treatment of children and adults with growth ...

Please provide your email address to receive an email when new articles are posted on . Novo Nordisk has announced the availability of somatropin injection 30 mg/3 mL in a prefilled, preloaded pen for ...

Ferring Enters U.S. Pediatric Endocrinology Market with Acquisition from Teva Pharmaceutical Industries Ltd. PARSIPPANY, N.J., March XX, 2015 – Ferring Pharmaceuticals Inc. today announced U.S. Food ...

Feb. 24, 2005 — The U.S. Food and Drug Administration (FDA) approved in November and December 2004 revisions to safety labeling to advise healthcare professionals of the following changes: use of ...

SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global somatropin market is estimated to be valued at US$ 5.02 billion in 2020 and is expected to exhibit a CAGR of 7.9% during the ...

COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment ...